Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts Brigham and Women's Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts